Theraclion SA (EPA:ALTHE)
France
· Delayed Price · Currency is EUR 0.512
+0.032 (6.67%)
Apr 28, 2026, 5:35 PM CET
Theraclion Revenue
In the year 2025, Theraclion had annual revenue of 2.32M EUR with 179.33% growth. Theraclion had revenue of 1.38M in the half year ending December 31, 2025, with 63.46% growth.
Revenue
2.32M
Revenue Growth
+179.33%
P/S Ratio
13.37
Revenue / Employee
72.47K
Employees
31
Market Cap
31.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.32M | 1.49M | 179.33% |
| Dec 31, 2024 | 830.21K | -992.01K | -54.44% |
| Dec 31, 2023 | 1.82M | 586.77K | 47.49% |
| Dec 31, 2022 | 1.24M | -245.50K | -16.58% |
| Dec 31, 2021 | 1.48M | 736.95K | 99.05% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Implanet | 12.47M |
| Novacyt | 22.69M |
| Diagnostic Medical Systems | 49.47M |
| Ikonisys | 1.47M |
| Mauna Kea Technologies | 8.91M |
| Biosynex | 97.95M |
| SpineGuard | 3.76M |
| Bluelinea Société Anonyme | 11.68M |
Theraclion News
- 14 hours ago - Theraclion’s non-invasive varicose treatment poised for FDA decision - The Armchair Trader